Rigel Pharmaceuticals | RIGL - Trade Debtors


Rigel Pharmaceuticals reported $28.9M in Trade Debtors for its fiscal quarter ending in June of 2024.





Trade Debtors Change Date
Agenus USD 22.44M 1.14M Dec/2025
Amgen USD 9.57B 1.08B Dec/2025
Anika Therapeutics USD 29.33M 661K Dec/2025
Arrowhead Research USD 218.87M 212.05M Dec/2025
AstraZeneca USD 19.05B 1.49B Dec/2025
BioMarin Pharmaceutical USD 908.21M 117.95M Dec/2025
Bristol-Myers Squibb USD 14.62B 485M Sep/2025
Celldex Therapeutics USD 2.02M 1.92M Dec/2025
Daiichi Sankyo JPY 695.95B 79.1B Dec/2025
Eli Lilly USD 19.46B 2.25B Sep/2025
Halozyme Therapeutics USD 441.27M 95.24M Dec/2025
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Intrexon USD 1.02M 559K Jun/2024
Ionis Pharmaceuticals USD 66M 41.39M Dec/2025
Karyopharm Therapeutics USD 26.18M 5.6M Dec/2025
Ligand Pharmaceuticals USD 58.1M 15.98M Sep/2025
MacroGenics USD 13.37M 55.86M Dec/2025
Neurocrine Biosciences USD 686.8M 41.2M Dec/2025
Pfizer USD 18.12B 2.02B Sep/2025
Regeneron Pharmaceuticals USD 5.74B 54M Dec/2025
Rigel Pharmaceuticals USD 28.9M 1.39M Jun/2024
Sangamo BioSciences USD 581K 110K Jun/2024
Ultragenyx Pharmaceutical USD 112.54M 11.92M Sep/2025
Veracyte USD 44.66M 3.17M Dec/2025